Evidence map›Paper›PMID 40142113›Full record

ArticleMolecules (Basel, Switzerland)2025

Integrating Surface Plasmon Resonance and Docking Analysis for Mechanistic Insights of Tryptase Inhibitors.

Alessia Porta, Candida Manelfi, Carmine Talarico, Andrea Rosario Beccari, Margherita Brindisi, Vincenzo Summa, Daniela Iaconis, Marco Gobbi, Marten Beeg

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alessia PortaIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156 Milano, Italy.ORCID 0009-0005-6730-3705
Candida ManelfiEXSCALATE-Dompé Farmaceutici SpA, via Tommaso De Amicis 95, 80131 Napoli, Italy.
Carmine TalaricoEXSCALATE-Dompé Farmaceutici SpA, via Tommaso De Amicis 95, 80131 Napoli, Italy.ORCID 0000-0003-4789-0955
Andrea Rosario BeccariEXSCALATE-Dompé Farmaceutici SpA, via Tommaso De Amicis 95, 80131 Napoli, Italy.ORCID 0000-0001-6830-2695
Margherita BrindisiDepartment of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy.ORCID 0000-0001-9119-3773
Vincenzo SummaDepartment of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy.ORCID 0000-0002-6288-2681
Daniela IaconisEXSCALATE-Dompé Farmaceutici SpA, via Tommaso De Amicis 95, 80131 Napoli, Italy.ORCID 0000-0002-1052-6634
Marco GobbiIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156 Milano, Italy.ORCID 0000-0003-1014-6225
Marten BeegIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156 Milano, Italy.ORCID 0000-0001-7201-6704

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tryptase is a tetrameric serine protease and a key component of mast cell granules. Here, we explored an integrated approach to characterize tryptase ligands, combining novel experimental binding studies using Surface Plasmon Resonance, with in silico analysis through the Exscalate platform. For this, we focused on three inhibitors previously reported in the literature, including a bivalent inhibitor and its corresponding monovalent compound. All three ligands showed concentration-dependent binding to immobilized human tryptase with the bivalent inhibitor showing the highest affinity. Furthermore, Rmax values were similar, indicating that the compounds occupy all four binding pockets of the tryptase tetramer. This hypothesis was supported by in silico computational analysis that revealed the binding mode of the monovalent ligand, one in each monomer pocket, compared with crystal structure of the bivalent one, which simultaneously occupies two binding pockets. Additionally, we solved the 2.06 Å X-ray crystal structures of human Tryptase beta-2 (hTPSB2), in both its apo form and in complex with compound #

Indexed as

Molecular Docking SimulationSerine Proteinase InhibitorsSurface Plasmon ResonanceTryptasesBinding SitesCrystallography, X-RayHumansLigandsProtein BindingLigandsSerine Proteinase InhibitorsTryptasesin silico dockingmolecular interactionsmolecular modelingsurface plasmon resonancetryptase inhibitorsX-ray crystal structures

Identifiers

PMID40142113
PMCPMC11944677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.